SCHEMBL9945526

SCHEMBL9945526

O=C(Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)C(O)[C@H]1O)c1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.72
SLC29A1 Q99808 2/20 0.72
TSHR P16473 2/20 0.72
NFKB1 P19838 2/20 0.72
THPO P40225 2/20 0.72
ALDH1A1 P00352 1/20 0.72
GLA P06280 1/20 0.72
PMP22 Q01453 1/20 0.72
SMN1; SMN2 Q16637 1/20 0.72
NPC1 O15118 1/20 0.72
NPY1R P25929 1/20 0.72
HTT P42858 1/20 0.72
NPY2R P49146 1/20 0.72
RAB9A P51151 1/20 0.72
RXFP1 Q9HBX9 1/20 0.72
CYP1A2 P05177 1/20 0.72
MAPK1 P28482 1/20 0.72
CYP2C19 P33261 1/20 0.72
ADORA3 P0DMS8 4/20 0.69
TP53 P04637 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29617913 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL27986516 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL17889837 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL313413 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL6909853 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL17301042 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL19485512 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL233209 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL21953578 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO
SCHEMBL233208 1.00 LMNA (0.72) LMNASLC29A1TSHRNFKB1THPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149888-A1 SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS CHEMGENES CORPORATION 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149888-A1 SYNTHESIS OF ARA-2'-O-METHYL-NUCLEOSIDES, CORRESPONDING PHOSPHORAMIDITES AND OLIGONUCLEOTIDES INCORPORATING NOVEL MODIFICATIONS FOR BIOLOGICAL APPLICATION IN THERAPEUCTICS, DIAGNOSTICS, G- TETRAD FORMING OLIGONUCLEOTIDES AND APTAMERS TYMP, MTAP, GART LMNA 2472/4885SLC29A1 381/4885TSHR 1578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.